{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:28:34Z","timestamp":1790278114084,"version":"4.1.0"},"reference-count":118,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Flavonoids are a family of secondary metabolites found in plants and fungi that exhibit\nstrong antioxidant properties and low toxicity, making them potential candidates for medicinal\nuse. Quercetin, a flavonoid present in various plant-based foods, has gained attention for its numerous\nbiological benefits, including anti-inflammatory, anti-fibrosis, and antioxidant properties.\nThe ocular surface research community has recently focused on quercetin\u2019s therapeutic potential\nfor managing ocular diseases, such as dry eye, keratoconus, corneal inflammation, and neovascularization.\nIn this paper, we discuss the role of quercetin for ocular disease prevention, highlighting\nits fundamental characteristics, common biological properties, and recent applications. By reviewing\nthe latest research conducted in the last 10 years which was focused on novel herbal formulations\nfor ocular diseases, we aim to provide insights into the role of quercetin in managing\nocular diseases and offer perspectives on its potential as a therapeutic agent.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2589977515666230822114324","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T05:51:47Z","timestamp":1692769907000},"page":"164-174","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoteric Role of Quercetin in Visual Disorders"],"prefix":"10.2174","volume":"16","author":[{"given":"Noor Hassan Sulaiman","family":"Khil","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaweta","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Aftab","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.ophtha.2013.05.025","volume":"120","author":"Stevens G.A.","year":"2013","unstructured":"Stevens G.A.; White R.A.; Flaxman S.R.; Global prevalence of vision impairment and blindness: Magnitude and temporal trends, 1990-2010. Ophthalmology  2013,120(12),2377-2384","journal-title":"Ophthalmology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"E820","DOI":"10.1208\/aapsj070479","volume":"7","author":"Bodor N.","year":"2005","unstructured":"Bodor N.; Buchwald P.; Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS J  2005,7(4),E820-E833","journal-title":"AAPS J"},{"key":"ref=3","first-page":"2","volume":"59","author":"Coroi M.C.","year":"2015","unstructured":"Coroi M.C.; Bungau S.; Tit M.; Preservatives from the eye drops and the ocular surface. Rom J Ophthalmol  2015,59(1),2-5","journal-title":"Rom J Ophthalmol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/861904","volume":"2014","author":"Baranowski P.","year":"2014","unstructured":"Baranowski P.; Karolewicz B.; Gajda M.; Pluta J.; Ophthalmic drug dosage forms: Characterisation and research methods. ScientificWorldJournal  2014,2014,1-14","journal-title":"ScientificWorldJournal"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/0973-7847.194044","volume":"10","author":"Parasuraman S.","year":"2016","unstructured":"Parasuraman S.; Anand David A.V.; Arulmoli R.; Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn Rev  2016,10(20),84-89","journal-title":"Pharmacogn Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8278454","volume":"2019","author":"Yeung A.W.K.","year":"2019","unstructured":"Yeung A.W.K.; Tzvetkov N.T.; El-Tawil O.S.; Bung\u01ceu S.G.; Abdel-Daim M.M.; Atanasov A.G.; Antioxidants: Scientific literature landscape analysis. Oxid Med Cell Longev  2019,2019,1-11","journal-title":"Oxid Med Cell Longev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/nu8030167","volume":"8","author":"Li Y.","year":"2016","unstructured":"Li Y.; Yao J.; Han C.; Quercetin, inflammation and immunity. Nutrients  2016,8(3),167","journal-title":"Nutrients"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ejmech.2018.06.053","volume":"155","author":"Patel R.V.","year":"2018","unstructured":"Patel R.V.; Mistry B.M.; Shinde S.K.; Syed R.; Singh V.; Shin H.S.; Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem  2018,155,889-904","journal-title":"Eur J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2174\/1386207322666190717124507","volume":"22","author":"Wu X.J.","year":"2019","unstructured":"Wu X.J.; Zhou X.B.; Chen C.; Mao W.; Systematic investigation of quercetin for treating cardiovascular disease based on network pharmacology. Comb Chem High Throughput Screen  2019,22(6),411-420","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/molecules21010108","volume":"21","author":"Nam J.S.","year":"2016","unstructured":"Nam J.S.; Sharma A.; Nguyen L.; Chakraborty C.; Sharma G.; Lee S.S.; Application of bioactive quercetin in oncotherapy: From nutrition to nanomedicine. Molecules  2016,21(1),108","journal-title":"Molecules"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2986796","DOI":"10.1155\/2016\/2986796","volume":"2016","author":"Costa L.G.","year":"2016","unstructured":"Costa L.G.; Garrick J.M.; Roqu\u00e8 P.J.; Pellacani C.; Mechanisms of neuroprotection by quercetin: Counteracting oxidative stress and more. Oxid Med Cell Longev  2016,2016,2986796","journal-title":"Oxid Med Cell Longev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1535370216685187","volume":"242","author":"McKay T.B.","year":"2017","unstructured":"McKay T.B.; Karamichos D.; Quercetin and the ocular surface: What we know and where we are going. Exp Biol Med  2017,242(6),565-572","journal-title":"Exp Biol Med"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"105074","DOI":"10.1016\/j.ejps.2019.105074","volume":"140","author":"Zhou Y.","year":"2019","unstructured":"Zhou Y.; Lu N.; Zhang H.; Corrigendum to \u201cHQS-3, a newly synthesized flavonoid, possesses potent anti-tumor effect in vivo and in vitro\u201d [European Journal of Pharmaceutical Science (2013) 649-658]. Eur J Pharm Sci  2019,140,105074","journal-title":"Eur J Pharm Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/mmr.2013.1846","volume":"9","author":"Wang L.","year":"2014","unstructured":"Wang L.; Cheng X.; Li H.; Quercetin reduces oxidative stress and inhibits activation of c-Jun N-terminal kinase\/activator protein-1 signaling in an experimental mouse model of abdominal aortic aneurysm. Mol Med Rep  2014,9(2),435-442","journal-title":"Mol Med Rep"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.clindermatol.2014.10.006","volume":"33","author":"Kels B.D.","year":"2015","unstructured":"Kels B.D.; Grzybowski A.; Grant-Kels J.M.; Human ocular anatomy. Clin Dermatol  2015,33(2),140-146","journal-title":"Clin Dermatol"},{"key":"ref=16","first-page":"439","volume":"58","author":"Kunti\u0107 V.","year":"2003","unstructured":"Kunti\u0107 V.; Peji\u0107 N.; Mi\u0107i\u0107 S.; Male\u0161ev D.; Vuji\u0107 Z.; Determination of dissociation constants of quercetin. Pharmazie  2003,58(6),439-440","journal-title":"Pharmazie"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.2147\/IJN.S285134","volume":"15","author":"Nie X.","year":"2020","unstructured":"Nie X.; Chen Z.; Pang L.; Oral Nano drug delivery systems for the treatment of type 2 diabetes mellitus: An available administration strategy for antidiabetic phytocompounds. Int J Nanomedicine  2020,15,10215-10240","journal-title":"Int J Nanomedicine"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.1021\/acsomega.0c01818","volume":"5","author":"Salehi B.","year":"2020","unstructured":"Salehi B.; Machin L.; Monzote L.; Therapeutic potential of quercetin: New insights and perspectives for human health. ACS Omega  2020,5(20),11849-11872","journal-title":"ACS Omega"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/17425247.5.5.567","volume":"5","author":"Barar J.","year":"2008","unstructured":"Barar J.; Javadzadeh A.R.; Omidi Y.; Ocular novel drug delivery: Impacts of membranes and barriers. Expert Opin Drug Deliv  2008,5(5),567-581","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","volume":"12","author":"Gaudana R.","year":"2010","unstructured":"Gaudana R.; Ananthula H.K.; Parenky A.; Mitra A.K.; Ocular drug delivery. AAPS J  2010,12(3),348-360","journal-title":"AAPS J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/0975-7406.111824","volume":"5","author":"Aqil M.","year":"2013","unstructured":"Aqil M.; Gupta H.; Khar R.; Ali A.; Bhatnagar A.; Mittal G.; Nanoparticles laden in situ gel for sustained ocular drug delivery. J Pharm Bioallied Sci  2013,5(2),162-165","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/978-3-642-69222-2_2","volume":"69","author":"Maurice D.M.","year":"1984","unstructured":"Maurice D.M.; Mishima S.; Ocular pharmacokinetics. In: Pharmacology of the Eye  1984,69,16-119","journal-title":"In: Pharmacology of the Eye"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","volume":"58","author":"Urtti A.","year":"2006","unstructured":"Urtti A.; Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev  2006,58(11),1131-1135","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.tifs.2021.11.032","volume":"119","author":"Kandemir K.","year":"2022","unstructured":"Kandemir K.; Tomas M.; McClements D.J.; Capanoglu E.; Recent advances on the improvement of quercetin bioavailability. Trends Food Sci Technol  2022,119,192-200","journal-title":"Trends Food Sci Technol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"230S","DOI":"10.1093\/ajcn\/81.1.230S","volume":"81","author":"Manach C.","year":"2005","unstructured":"Manach C.; Williamson G.; Morand C.; Scalbert A.; R\u00e9m\u00e9sy C.; Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr  2005,81(1),230S-242S","journal-title":"Am J Clin Nutr"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/ajcn\/62.6.1276","volume":"62","author":"Hollman P.C.","year":"1995","unstructured":"Hollman P.C.; de Vries J.H.; van Leeuwen S.D.; Mengelers M.J.; Katan M.B.; Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr  1995,62(6),1276-1282","journal-title":"Am J Clin Nutr"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0003-9861(03)00284-4","volume":"417","author":"Murota K.","year":"2003","unstructured":"Murota K.; Terao J.; Antioxidative flavonoid quercetin: Implication of its intestinal absorption and metabolism. Arch Biochem Biophys  2003,417(1),12-17","journal-title":"Arch Biochem Biophys"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10715760100301441","volume":"35","author":"Day A.J.","year":"2001","unstructured":"Day A.J.; Mellon F.; Barron D.; Sarrazin G.; Morgan M.R.A.; Williamson G.; Human metabolism of dietary flavonoids: Identification of plasma metabolites of quercetin. Free Radic Res  2001,35(6),941-952","journal-title":"Free Radic Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/10715760410001728415","volume":"38","author":"Janisch K.M.","year":"2004","unstructured":"Janisch K.M.; Williamson G.; Needs P.; Plumb G.W.; Properties of quercetin conjugates: Modulation of LDL oxidation and binding to human serum albumin. Free Radic Res  2004,38(8),877-884","journal-title":"Free Radic Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1104\/pp.126.2.485","volume":"126","author":"Winkel-Shirley B.","year":"2001","unstructured":"Winkel-Shirley B.; Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol  2001,126(2),485-493","journal-title":"Plant Physiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1369-5266(02)00256-X","volume":"5","author":"Winkel-Shirley B.","year":"2002","unstructured":"Winkel-Shirley B.; Biosynthesis of flavonoids and effects of stress. Curr Opin Plant Biol  2002,5(3),218-223","journal-title":"Curr Opin Plant Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1472-8206.1998.tb00951.x","volume":"12","author":"Groot H.","year":"1998","unstructured":"Groot H.; Rauen U.; Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam Clin Pharmacol  1998,12(3),249-255","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1360-1385(97)01018-2","volume":"2","author":"Rice-Evans C.","year":"1997","unstructured":"Rice-Evans C.; Miller N.; Paganga G.; Antioxidant properties of phenolic compounds. Trends Plant Sci  1997,2(4),152-159","journal-title":"Trends Plant Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0378-4347(00)00549-1","volume":"753","author":"Wittig J.","year":"2001","unstructured":"Wittig J.; Herderich M.; Graefe E.U.; Veit M.; Identification of quercetin glucuronides in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr, Biomed Appl  2001,753(2),237-243","journal-title":"J Chromatogr, Biomed Appl"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1139\/y2012-101","volume":"90","author":"Kukongviriyapan U.","year":"2012","unstructured":"Kukongviriyapan U.; Sompamit K.; Pannangpetch P.; Kukongviriyapan V.; Donpunha W.; Preventive and therapeutic effects of quercetin on lipopolysaccharide-induced oxidative stress and vascular dysfunction in mice. Can J Physiol Pharmacol  2012,90(10),1345-1353","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbi.2005.12.009","volume":"160","author":"Valko M.","year":"2006","unstructured":"Valko M.; Rhodes C.J.; Moncol J.; Izakovic M.; Mazur M.; Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact  2006,160(1),1-40","journal-title":"Chem Biol Interact"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0891-5849(96)00129-3","volume":"21","author":"Hollman P.C.H.","year":"1996","unstructured":"Hollman P.C.H.; Gaag M.V.D.; Mengelers M.J.B.; Van Trijp J.M.P.; De Vries J.H.M.; Katan M.B.; Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic Biol Med  1996,21(5),703-707","journal-title":"Free Radic Biol Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/10715760290025951","volume":"36","author":"Heijnen C.G.M.","year":"2002","unstructured":"Heijnen C.G.M.; Haenen G.R.M.M.; Minou Oostveen R.; Stalpers E.M.; Bast A.; Protection of flavonoids against lipid peroxidation: The structure activity relationship revisited. Free Radic Res  2002,36(5),575-581","journal-title":"Free Radic Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.foodchem.2004.02.008","volume":"88","author":"Arts M.J.T.J.","year":"2004","unstructured":"Arts M.J.T.J.; Sebastiaan Dallinga J.; Voss H.P.; Haenen G.R.M.M.; Bast A.; A new approach to assess the total antioxidant capacity using the TEAC assay. Food Chem  2004,88(4),567-570","journal-title":"Food Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.phrs.2009.10.005","volume":"61","author":"Rogerio A.P.","year":"2010","unstructured":"Rogerio A.P.; Dora C.L.; Andrade E.L.; Anti-inflammatory effect of quercetin-loaded microemulsion in the airways allergic inflammatory model in mice. Pharmacol Res  2010,61(4),288-297","journal-title":"Pharmacol Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/0253-7613.77365","volume":"43","author":"Sah S.","year":"2011","unstructured":"Sah S.; Tirkey N.; Kuhad A.; Chopra K.; Effect of quercetin on lipopolysaccharide induced-sickness behavior and oxidative stress in rats. Indian J Pharmacol  2011,43(2),192-196","journal-title":"Indian J Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/jn\/137.10.2190","volume":"137","author":"Geraets L.","year":"2007","unstructured":"Geraets L.; Moonen H.J.J.; Brauers K.; Wouters E.F.M.; Bast A.; Hageman G.J.; Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J Nutr  2007,137(10),2190-2195","journal-title":"J Nutr"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/jnr.21503","volume":"86","author":"Bureau G.","year":"2008","unstructured":"Bureau G.; Longpr\u00e9 F.; Martinoli M.G.; Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res  2008,86(2),403-410","journal-title":"J Neurosci Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/eji.200425778","volume":"35","author":"Comalada M.","year":"2005","unstructured":"Comalada M.; Camuesco D.; Sierra S.; In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-\u03baB pathway. Eur J Immunol  2005,35(2),584-592","journal-title":"Eur J Immunol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0014-2999(01)01320-6","volume":"429","author":"MacNee W.","year":"2001","unstructured":"MacNee W.; Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol  2001,429(1-3),195-207","journal-title":"Eur J Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/rheumatology\/kem014","volume":"46","author":"Xu H.","year":"2007","unstructured":"Xu H.; He Y.; Yang X.; Anti-malarial agent artesunate inhibits TNF- -induced production of proinflammatory cytokines via inhibition of NF- B and PI3 kinase\/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology  2007,46(6),920-926","journal-title":"Rheumatology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1128\/CVI.13.3.319-328.2006","volume":"13","author":"Nair M.P.","year":"2006","unstructured":"Nair M.P.; Mahajan S.; Reynolds J.L.; The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-\u03ba \u03b2 system. Clin Vaccine Immunol  2006,13(3),319-328","journal-title":"Clin Vaccine Immunol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecam\/neq053","volume":"2011","author":"Gibellini L.","year":"2011","unstructured":"Gibellini L.; Pinti M.; Nasi M.; Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med  2011,2011,1-15","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=49","first-page":"146","volume":"1","author":"Baghel S.S.","year":"2012","unstructured":"Baghel S.S.; Shrivastava N.; Baghel R.S.; Agrawal P.; Rajput S.; A review of quercetin: Antioxidant and anticancer properties. World J Pharm Pharm Sci  2012,1(1),146-160","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jcb.21977","volume":"106","author":"Jeong J.H.","year":"2009","unstructured":"Jeong J.H.; An J.Y.; Kwon Y.T.; Rhee J.G.; Lee Y.J.; Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression. J Cell Biochem  2009,106(1),73-82","journal-title":"J Cell Biochem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.gene.2015.12.012","volume":"577","author":"Li C.","year":"2016","unstructured":"Li C.; Wang T.; Zhang C.; Xuan J.; Su C.; Wang Y.; Quercetin attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Gene  2016,577(2),275-280","journal-title":"Gene"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11033-015-3921-7","volume":"42","author":"Maurya A.K.","year":"2015","unstructured":"Maurya A.K.; Vinayak M.; Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep  2015,42(9),1419-1429","journal-title":"Mol Biol Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1039\/D0FO01118E","volume":"11","author":"Parmenter B.H.","year":"2020","unstructured":"Parmenter B.H.; Croft K.D.; Hodgson J.M.; An overview and update on the epidemiology of flavonoid intake and cardiovascular disease risk. Food Funct  2020,11(8),6777-6806","journal-title":"Food Funct"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jn\/137.11.2405","volume":"137","author":"Edwards R.L.","year":"2007","unstructured":"Edwards R.L.; Lyon T.; Litwin S.E.; Rabovsky A.; Symons J.D.; Jalili T.; Quercetin reduces blood pressure in hypertensive subjects. J Nutr  2007,137(11),2405-2411","journal-title":"J Nutr"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1017\/S0007114509359127","volume":"102","author":"Egert S.","year":"2009","unstructured":"Egert S.; Bosy-Westphal A.; Seiberl J.; Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study. Br J Nutr  2009,102(7),1065-1074","journal-title":"Br J Nutr"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/ijo.2010.272","volume":"35","author":"Overman A.","year":"2011","unstructured":"Overman A.; Chuang C-C.; McIntosh M.; Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media. Int J Obes  2011,35(9),1165-1172","journal-title":"Int J Obes"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3945\/ajcn.2010.29807","volume":"92","author":"Chuang C.C.","year":"2010","unstructured":"Chuang C.C.; Martinez K.; Xie G.; Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-\u03b1\u2013mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr  2010,92(6),1511-1521","journal-title":"Am J Clin Nutr"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejphar.2010.02.019","volume":"635","author":"Prince P.S.M.","year":"2010","unstructured":"Prince P.S.M.; Sathya B.; Pretreatment with quercetin ameliorates lipids, lipoproteins and marker enzymes of lipid metabolism in isoproterenol treated cardiotoxic male Wistar rats. Eur J Pharmacol  2010,635(1-3),142-148","journal-title":"Eur J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2011.04.023","volume":"218","author":"Kleemann R.","year":"2011","unstructured":"Kleemann R.; Verschuren L.; Morrison M.; Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis  2011,218(1),44-52","journal-title":"Atherosclerosis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/bjo.83.1.62","volume":"83","author":"McCarty C.A.","year":"1999","unstructured":"McCarty C.A.; Keeffe J.E.; Taylor H.R.; The need for cataract surgery: Projections based on lens opacity, visual acuity, and personal concern. Br J Ophthalmol  1999,83(1),62-65","journal-title":"Br J Ophthalmol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/nu11051186","volume":"11","author":"Braakhuis A.J.","year":"2019","unstructured":"Braakhuis A.J.; Donaldson C.I.; Lim J.C.; Donaldson P.J.; Nutritional strategies to prevent lens cataract: Current status and future strategies. Nutrients  2019,11(5),1186","journal-title":"Nutrients"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/nure.12077","volume":"72","author":"Weikel K.A.","year":"2014","unstructured":"Weikel K.A.; Garber C.; Baburins A.; Taylor A.; Nutritional modulation of cataract. Nutr Rev  2014,72(1),30-47","journal-title":"Nutr Rev"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fphar.2019.00466","volume":"10","author":"Tewari D.","year":"2019","unstructured":"Tewari D.; Samoil\u0103 O.; Gocan D.; Medicinal plants and natural products used in cataract management. Front Pharmacol  2019,10,466","journal-title":"Front Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ph13010015","volume":"13","author":"Heruye S.H.","year":"2020","unstructured":"Heruye S.H.; Maffofou Nkenyi L.N.; Singh N.U.; Current trends in the pharmacotherapy of cataracts. Pharmaceuticals  2020,13(1),15","journal-title":"Pharmaceuticals"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0140-6736(17)30544-5","volume":"390","author":"Liu Y.C.","year":"2017","unstructured":"Liu Y.C.; Wilkins M.; Kim T.; Malyugin B.; Mehta J.S.; Cataracts. Lancet  2017,390(10094),600-612","journal-title":"Lancet"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.exer.2004.12.007","volume":"80","author":"Truscott R.J.W.","year":"2005","unstructured":"Truscott R.J.W.; Age-related nuclear cataract\u2014oxidation is the key. Exp Eye Res  2005,80(5),709-725","journal-title":"Exp Eye Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.exer.2016.01.012","volume":"145","author":"Ferlemi A.V.","year":"2016","unstructured":"Ferlemi A.V.; Makri O.E.; Mermigki P.G.; Lamari F.N.; Georgakopoulos C.D.; Quercetin glycosides and chlorogenic acid in highbush blueberry leaf decoction prevent cataractogenesis in vivo and in vitro: Investigation of the effect on calpains, antioxidant and metal chelating properties. Exp Eye Res  2016,145,258-268","journal-title":"Exp Eye Res"},{"key":"ref=68","first-page":"1","volume":"9","author":"Patil KK","year":"2019","unstructured":"Patil KK; Meshram RJ; Barage SH; Gacche RN; Dietary flavonoids\ninhibit the glycation of lens proteins: Implications in the management\nof diabetic cataract. 3 Biotech  2019,9(2),1-5","journal-title":"3 Biotech"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1248\/cpb.50.788","volume":"50","author":"Matsuda H.","year":"2002","unstructured":"Matsuda H.; Morikawa T.; Toguchida I.; Yoshikawa M.; Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem Pharm Bull  2002,50(6),788-795","journal-title":"Chem Pharm Bull"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"Weinreb R.N.","year":"2014","unstructured":"Weinreb R.N.; Aung T.; Medeiros F.A.; The pathophysiology and treatment of glaucoma: A review. JAMA  2014,311(18),1901-1911","journal-title":"JAMA"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1874364101004010052","volume":"4","author":"Goel M.","year":"2010","unstructured":"Goel M.; Picciani R.G.; Lee R.K.; Bhattacharya S.K.; Aqueous humor dynamics: A review. Open Ophthalmol J  2010,4(1),52-59","journal-title":"Open Ophthalmol J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4103\/0301-4738.41411","volume":"56","author":"Gadia R.","year":"2008","unstructured":"Gadia R.; Sihota R.; Dada T.; Gupta V.; Current profile of secondary glaucomas. Indian J Ophthalmol  2008,56(4),285-289","journal-title":"Indian J Ophthalmol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fnins.2019.00672","volume":"13","author":"Zhou X.","year":"2019","unstructured":"Zhou X.; Li G.; Yang B.; Wu J.; Quercetin enhances inhibitory synaptic inputs and reduces excitatory synaptic inputs to OFF-and ON-type retinal ganglion cells in a chronic glaucoma rat model. Front Neurosci  2019,13,672","journal-title":"Front Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fnmol.2017.00285","volume":"10","author":"Gao F.J.","year":"2017","unstructured":"Gao F.J.; Zhang S.H.; Xu P.; Quercetin declines apoptosis, ameliorates mitochondrial function and improves retinal ganglion cell survival and function in in vivo model of glaucoma in rat and retinal ganglion cell culture in vitro. Front Mol Neurosci  2017,10,285","journal-title":"Front Mol Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"Stapleton F.","year":"2017","unstructured":"Stapleton F.; Alves M.; Bunya V.Y.; Tfos dews II epidemiology report. Ocul Surf  2017,15(3),334-365","journal-title":"Ocul Surf"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"Craig J.P.","year":"2017","unstructured":"Craig J.P.; Nichols K.K.; Akpek E.K.; TFOS DEWS II definition and classification report. Ocul Surf  2017,15(3),276-283","journal-title":"Ocul Surf"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13167-016-0065-3","volume":"7","author":"Hagan S.","year":"2016","unstructured":"Hagan S.; Martin E.; Enr\u00edquez-de-Salamanca A.; Tear fluid biomarkers in ocular and systemic disease: Potential use for predictive, preventive and personalised medicine. EPMA J  2016,7(1),15","journal-title":"EPMA J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2018.10.026","volume":"292","author":"Guo H.","year":"2018","unstructured":"Guo H.; Lee C.; Shah M.; A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sj\u00f6gren\u2019s syndrome. J Control Release  2018,292,183-195","journal-title":"J Control Release"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICU.0000000000000569","volume":"30","author":"O\u2019Neil E.C.","year":"2019","unstructured":"O\u2019Neil E.C.; Henderson M.; Massaro-Giordano M.; Bunya V.Y.; Advances in dry eye disease treatment. Curr Opin Ophthalmol  2019,30(3),166-178","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/ICO.0000000000000543","volume":"34","author":"Oh H.N.","year":"2015","unstructured":"Oh H.N.; Kim C.E.; Lee J.H.; Yang J.W.; Effects of quercetin in a mouse model of experimental dry eye. Cornea  2015,34(9),1130-1136","journal-title":"Cornea"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2018.1497664","volume":"27","author":"Abeng\u00f3zar-Vela A.","year":"2019","unstructured":"Abeng\u00f3zar-Vela A.; Schaumburg C.S.; Stern M.E.; Calonge M.; Enr\u00edquez-de-Salamanca A.; Gonz\u00e1lez-Garc\u00eda M.J.; Topical quercetin and resveratrol protect the ocular surface in experimental dry eye disease. Ocul Immunol Inflamm  2019,27(6),1023-1032","journal-title":"Ocul Immunol Inflamm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ajo.2006.02.047","volume":"142","author":"Garrity J.A.","year":"2006","unstructured":"Garrity J.A.; Bahn R.S.; Pathogenesis of graves ophthalmopathy: Implications for prediction, prevention, and treatment. Am J Ophthalmol  2006,142(1),147-153.e2","journal-title":"Am J Ophthalmol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"Bahn R.S.","year":"2010","unstructured":"Bahn R.S.; Graves\u2019 ophthalmopathy. N Engl J Med  2010,362(8),726-738","journal-title":"N Engl J Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/thy.2007.0407","volume":"18","author":"Lehmann G.M.","year":"2008","unstructured":"Lehmann G.M.; Feldon S.E.; Smith T.J.; Phipps R.P.; Immune mechanisms in thyroid eye disease. Thyroid  2008,18(9),959-965","journal-title":"Thyroid"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3928\/1542-8877-19950101-14","volume":"26","author":"Madhavan H.N.","year":"1995","unstructured":"Madhavan H.N.; Rao S.B.; Vijaya L.; Neelakantan A.; In vitro sensitivity of human Tenon\u2019s capsule fibroblasts to mitomycin C and its correlation with outcome of glaucoma filtration surgery. Ophthalmic Surg Lasers Imaging Retina  1995,26(1),61-67","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"Prabhakar B.S.","year":"2003","unstructured":"Prabhakar B.S.; Bahn R.S.; Smith T.J.; Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr Rev  2003,24(6),802-835","journal-title":"Endocr Rev"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1167\/iovs.12-9646","volume":"53","author":"Yoon J.S.","year":"2012","unstructured":"Yoon J.S.; Chae M.K.; Jang S.Y.; Lee S.Y.; Lee E.J.; Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves\u2019 orbitopathy. Invest Ophthalmol Vis Sci  2012,53(9),5921-5929","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/all.12077","volume":"68","author":"Cheng C.","year":"2013","unstructured":"Cheng C.; Ng D.S.W.; Chan T.K.; Anti-allergic action of anti-malarial drug artesunate in experimental mast cell-mediated anaphylactic models. Allergy  2013,68(2),195-203","journal-title":"Allergy"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1517\/14728210903103818","volume":"14","author":"Origlieri C.","year":"2009","unstructured":"Origlieri C.; Bielory L.; Emerging drugs for conjunctivitis. Expert Opin Emerg Drugs  2009,14(3),523-536","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000058748","volume":"73","author":"Liu G.","year":"1999","unstructured":"Liu G.; Keane-Myers A.; Miyazaki D.; Tai A.; Ono S.J.; Molecular and cellular aspects of allergic conjunctivitis. Chem Immunol  1999,73,39-58","journal-title":"Chem Immunol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"110924","DOI":"10.1016\/j.fct.2019.110924","volume":"135","author":"Ding Y.","year":"2020","unstructured":"Ding Y.; Li C.; Zhang Y.; Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis. Food Chem Toxicol  2020,135,110924","journal-title":"Food Chem Toxicol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1167\/iovs.15-16595","volume":"56","author":"Abeng\u00f3zar-Vela A.","year":"2015","unstructured":"Abeng\u00f3zar-Vela A.; Calonge M.; Stern M.E.; Gonz\u00e1lez-Garc\u00eda M.J.; Enr\u00edquez-De-Salamanca A.; Quercetin and resveratrol decrease the inflammatory and oxidative responses in human ocular surface epithelial cells. Invest Ophthalmol Vis Sci  2015,56(4),2709-2719","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pbc.21791","volume":"52","author":"Menon B.S.","year":"2009","unstructured":"Menon B.S.; Alagaratnam J.; Juraida E.; Mohamed M.; Ibrahim H.; Naing N.N.; Late presentation of retinoblastoma in Malaysia. Pediatr Blood Cancer  2009,52(2),215-217","journal-title":"Pediatr Blood Cancer"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0022-3476(98)70028-9","volume":"132","author":"Abramson D.H.","year":"1998","unstructured":"Abramson D.H.; Frank C.M.; Susman M.; Whalen M.P.; Dunkel I.J.; Boyd N.W.; Presenting signs of retinoblastoma. J Pediatr  1998,132(3),505-508","journal-title":"J Pediatr"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/bjo.2008.150292","volume":"93","author":"Kivel\u00e4 T.","year":"2009","unstructured":"Kivel\u00e4 T.; The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol  2009,93(9),1129-1131","journal-title":"Br J Ophthalmol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/bjo.2003.035642","volume":"88","author":"Leal-Leal C.","year":"2004","unstructured":"Leal-Leal C.; Flores-Rojo M.; Medina-Sans\u00f3n A.; A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol  2004,88(8),1074-1077","journal-title":"Br J Ophthalmol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/S0140-6736(11)61137-9","volume":"379","author":"Dimaras H.","year":"2012","unstructured":"Dimaras H.; Kimani K.; Dimba E.A.O.; Retinoblastoma. Lancet  2012,379(9824),1436-1446","journal-title":"Lancet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/01.icu.0000193079.55240.18","volume":"17","author":"Shields C.L.","year":"2006","unstructured":"Shields C.L.; Shields J.A.; Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol  2006,17(3),228-234","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.cca.2010.10.009","volume":"412","author":"Saxena P.","year":"2011","unstructured":"Saxena P.; Kaur J.; Differential expression of genes in retinoblastoma. Clin Chim Acta  2011,412(23-24),2015-2021","journal-title":"Clin Chim Acta"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12906-017-2023-6","volume":"17","author":"Liu H.","year":"2017","unstructured":"Liu H.; Zhou M.; Antitumor effect of Quercetin on Y79 retinoblastoma cells via activation of JNK and p38 MAPK pathways. BMC Complement Altern Med  2017,17(1),531","journal-title":"BMC Complement Altern Med"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jfo.2013.05.004","volume":"36","author":"Fourni\u00e9 P.","year":"2013","unstructured":"Fourni\u00e9 P.; Touboul D.; Arn\u00e9 J.L.; Colin J.; Malecaze F.; K\u00e9ratoc\u00f4ne. French J Ophthalmol  2013,36(7),618-626","journal-title":"French J Ophthalmol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/eye.2013.278","volume":"28","author":"Davidson A.E.","year":"2014","unstructured":"Davidson A.E.; Hayes S.; Hardcastle A.J.; Tuft S.J.; The pathogenesis of keratoconus. Eye  2014,28(2),189-195","journal-title":"Eye"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1038\/srep09003","volume":"5","author":"McKay T.B.","year":"2015","unstructured":"McKay T.B.; Lyon D.; Sarker-Nag A.; Priyadarsini S.; Asara J.M.; Karamichos D.; Quercetin attenuates lactate production and extracellular matrix secretion in keratoconus. Sci Rep  2015,5(1),9003","journal-title":"Sci Rep"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cbf.3122","volume":"33","author":"McKay T.B.","year":"2015","unstructured":"McKay T.B.; Sarker-Nag A.; Lyon D.; Asara J.M.; Karamichos D.; Quercetin modulates keratoconus metabolism in vitro. Cell Biochem Funct  2015,33(5),341-350","journal-title":"Cell Biochem Funct"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"111371","DOI":"10.1016\/j.biopha.2021.111371","volume":"137","author":"Zhao L.","year":"2021","unstructured":"Zhao L.; Wang H.; Du X.; The therapeutic use of quercetin in ophthalmology: Recent applications. Biomed Pharmacother  2021,137,111371","journal-title":"Biomed Pharmacother"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","volume":"51","author":"Pastor J.C.","year":"2016","unstructured":"Pastor J.C.; Rojas J.; Pastor-Idoate S.; Di Lauro S.; Gonzalez-Buendia L.; Delgado-Tirado S.; Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res  2016,51,125-155","journal-title":"Prog Retin Eye Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2017.08.001","volume":"60","author":"Shu D.Y.","year":"2017","unstructured":"Shu D.Y.; Lovicu F.J.; Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis. Prog Retin Eye Res  2017,60,44-65","journal-title":"Prog Retin Eye Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.2147\/DDDT.S185618","volume":"12","author":"Cai W.","year":"2018","unstructured":"Cai W.; Yu D.; Fan J.; Quercetin inhibits transforming growth factor \u03b21-induced epithelial\u2013mesenchymal transition in human retinal pigment epithelial cells via the Smad pathway. Drug Des Devel Ther  2018,12,4149-4161","journal-title":"Drug Des Devel Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e10136","DOI":"10.7717\/peerj.10136","volume":"8","author":"Zou H.","year":"2020","unstructured":"Zou H.; Shan C.; Ma L.; Liu J.; Yang N.; Zhao J.; Polarity and epithelial-mesenchymal transition of retinal pigment epithelial cells in proliferative vitreoretinopathy. PeerJ  2020,8,e10136","journal-title":"PeerJ"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"124","DOI":"10.18043\/ncm.78.2.124","volume":"78","author":"Bashinsky A.L.","year":"2017","unstructured":"Bashinsky A.L.; Retinopathy of prematurity. N C Med J  2017,78(2),124-128","journal-title":"N C Med J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000455278","volume":"58","author":"Jonas J.B.","year":"2017","unstructured":"Jonas J.B.; Mon\u00e9s J.; Glacet-Bernard A.; Coscas G.; Retinal vein occlusions. Dev Ophthalmol  2017,58,139-167","journal-title":"Dev Ophthalmol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5935\/0004-2749.20150026","volume":"78","author":"Arikan S.","year":"2015","unstructured":"Arikan S.; Ersan I.; Karaca T.; Quercetin protects the retina by reducing apoptosis due to ischemia-reperfusion injury in a rat model. Arq Bras Oftalmol  2015,78(2),100-104","journal-title":"Arq Bras Oftalmol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.exer.2014.06.009","volume":"125","author":"Kumar B.","year":"2014","unstructured":"Kumar B.; Gupta S.K.; Nag T.C.; Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. Exp Eye Res  2014,125,193-202","journal-title":"Exp Eye Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/bjo.87.3.312","volume":"87","author":"Owen C.G.","year":"2003","unstructured":"Owen C.G.; Fletcher A.E.; Donoghue M.; Rudnicka A.R.; How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol  2003,87(3),312-317","journal-title":"Br J Ophthalmol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","volume":"122","author":"Friedman D.S.","year":"2004","unstructured":"Friedman D.S.; O\u2019Colmain B.J.; Mu\u00f1oz B.; Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol  2004,122(4),564-572","journal-title":"Arch Ophthalmol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0002-9394(99)80239-6","volume":"125","author":"Thylefors B.","year":"1998","unstructured":"Thylefors B.; A global initiative for the elimination of avoidable blindness. Am J Ophthalmol  1998,125(1),90-93","journal-title":"Am J Ophthalmol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/archophthalmol.2010.18","volume":"128","author":"Gehrs K.M.","year":"2010","unstructured":"Gehrs K.M.; Jackson J.R.; Brown E.N.; Allikmets R.; Hageman G.S.; Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol  2010,128(3),349-358","journal-title":"Arch Ophthalmol"},{"key":"ref=118","first-page":"23","volume":"26","author":"Zhuang P.","year":"2011","unstructured":"Zhuang P.; Shen Y.; Lin B.Q.; Zhang W.Y.; Chiou G.C.; Effect of quercetin on formation of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Yan Ke Xue Bao  2011,26(1),23-29","journal-title":"Yan Ke Xue Bao"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977515666230822114324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220179\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977515666230822114324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T06:49:17Z","timestamp":1724136557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220179\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":118,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977515666230822114324","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}